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INTERLEUKIN-5 (IL-5) has been shown to be a selective
eosinophil growth and differentiation factor. In the present
study, the effect of recombinant human IL-5 on human
eosinophil sulfidopeptide leukotriene production was
investigated. IL-5 did not affect leukotriene synthesis in
unstimulated eosinophils. However, IL-5 potentiated
leukotriene synthesis by eosinophils stimulated with
serum treated zymosan (STZ) or the calcium ionophore
A23187 by 69% and 135%, respectively. The priming effect
of IL-5 was dose dependent, with significant stimulation
occurring at 1 000 U/ml for STZ and 100-1 000 U/ml for
A23187. Pre-incubation with IL-5 did not increase
leukotriene synthesis further.
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Introduction
Human eosinophils play an important role in the
pathogenesis of bronchial asthma. 1’2 Peripheral
blood and sputum eosinophilia often accompanies
asthma, a large number of eosinophils infiltrate the
airways during the late asthmatic reaction and
mediators released by these cells can affect airway
function.
2 Bronchospasmogenic substances such as
sulfidopeptide leukotrienes (LT) and platelet-
activating factor (PAF), as well as other eosinophil
derived mediators appear to play a role in the
development of airway hyperreactivity, a main
characteristic of bronchial asthma.
>3 Eosinophil
cytotoxic cationic proteins can damage airway
epithelial cells, which may cause airway hyper-
reactivity.
4-7 Furthermore, inhaled sulfidopeptide
leukotrienes and PAF are able to induce
airway hyperreactivity in laboratory animals and
humans, s-11
It has been demonstrated that eosinophils from
asthmatic patients are hypodense and produce more
leukotriene C4 and reactive oxygen metabolites than
those from healthy persons.
2 The mechanism
causing the eosinophilia and the primed state of
eosinophils in asthmatics is unknown. It has been
suggested that T-lymphocyte derived cytokines
may play an important role in this phenomenon.
2
T-lymphocytes are activated in acute asthma and
infiltrate the airways after allergen provocation,
2
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thus creating an ideal environment for eosinophil
proliferation and activation.
Several cytokines have been shown to induce
eosinophil proliferation, chemotaxis, activation and/
or priming.
>ls Granulocyte macrophage colony-
stimulating factor (GM-CSF), tumour necrosis
factor (TNF), interleukin-3 (IL-3) and IL-5 have all
been shown to regulate one or more eosinophil
functions.4,s Of these cytokines, only IL-5 seems
to be a selective activator of eosinophils, whereas
other cytokines also influence neutrophils. It has
been shown that IL-5 induces eosinophil prolifera-
tion, chemiluminescence, release of cytotoxic
cationic proteins, chemotaxis and cytotoxicity, and
enhances adhesion to endothelial cells.3’6-s In the
present study, the influence of IL-5 on serum-
treated zymosan (STZ) and calcium ionophore
(A23187) induced sulfidopeptide leukotriene pro-
duction by human eosinophils was investigated.
Materials and Methods
Eosinophils were isolated from blood of normal
human volunteers (Central Laboratory of the
Netherlands Red Cross Blood Transfusion Service,
Amsterdam and Bloodbank, Utrecht, the Nether-
lands) as described before in detail. 19 The purity of
the eosinophils was 95 _+ 3% and the viability was
always more than 95% as determined by trypan blue
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exclusion. For the production of leukotriene, 200 #1
of eosinophils (3 x 106 cells/ml) were incubated
(37C, constant agitation) with or without different
concentrations of recombinant human IL-5 (gener-
ously provided by Dr C. J. Sanderson, National
Institute for Medical Research, Mill Hill, London
NW7, UK). The cells were stimulated with either
serum treated zymosan (0.5 mg/ml final concentra-
tion) for 30 min or with the calcium ionophore
A23187 (2.5/,M) for 10 min in a final volume of
250/1. Incubations were terminated by cooling on
ice, and supernatants were collected by centrifuga-
tion at 8 000 x g for 1 min followed by storage
under nitrogen at -80C until analysis. The
amount of leukotriene C4/D4/E4 in the supernatants
was determined with a radioimmunoassay kit
according to the manufacturer’s instructions
(Amersham, Buckinghamshire, UK).
Results
Incubation of human eosinophils with IL-5 for
30 min at 10-1 000 U/ml itself induced a small but
not significant increase in leukotriene synthesis
(Table 1). However, IL-5 (1 000 U/ml) potentiated
STZ induced leukotriene synthesis by 69%
compared with the production of leukotriene in the
absence of the cytokine (Fig. 1). IL-5 (300 U/ml)
induced a potentiation of the calcium ionophore
induced leukotriene synthesis by 135% compared
with the production of leukotriene in the absence of
the cytokine. Pre-incubation of eosinophils with
IL-5 (1000U/ml) for 10min and subsequent
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FIG. 1. The effect of different concentrations of L-5 on human eosinophil
leukotriene C4/D4/E4 synthesis induced with (A) STZ (n 11) or (B)
calcium ionophore A23187 (n 4). Results are presented as means-I-
S.E.M. IL-5 and the stimulating agents were added simultaneously.
*p < 0.05 and **p < 0.01 as determined with the paired Student’s t-test
and compared with the leukotriene synthesis in the absence of IL-5.
Table 1. The direct effect of different
concentrations of L-5 on human eos-
inophil leukotriene C4/D4/E4 synthesis
(n=3)
L-5 LT synthesis
(U/ml) (pg/106 cells)
0 36.7 + 3.6
10 37.5 ___
3.2
100 42.3 ___
4.0
000 47.9-I- 2.7
Results are presented as means + S.E.M.
stimulation with STZ or A23187 showed a similar
potentiation of leukotriene synthesis as measured
without pre-incubation (Table 2). In pilot experi-
ments, longer pre-incubation times of eosinophils
with IL-5 (up to 60 min) did not show a further
enhancement of leukotriene synthesis. Leukotriene
synthesis by eosinophils decreased after pre-
incubation above 15 min. This was observed both
in the absence or presence of IL-5. There were
large donor-to-donor variations in eosinophil-
leukotriene production and its IL-5 enhancement
Table 2. The effect of pre-incubation time on human eosinophils with IL-5 on STZ- or
A23187-induced leukotriene C4/D4/E4 synthesis
STZ A23187
Pre-incubation
time (min) -IL-5 +IL-5 -IL-5 +IL-5
0 8.6 + 4.0 13.1 + 5.7* 15.8 _+ 6.4 56.5 + 14.8"
10 9.2 + 4.2 14.5 + 5.2** 12.4 + 4.2 52.9 + 6.8*
*p < 0.05 and **p < 0.01 as determined with the paired Student’s t-test and compared
with the control. Results (ng/106 cells) are expressed as mean -I- S.E.M. (n 6 for STZ,
n 3 for A23187). IL-5 was used as 000 U/ml.
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Table 3. Three individual experiments illustrating the donor-
to-donor variation in STZ-induced leukotriene C,/D,/E,
synthesis (ng/106 cells) and the enhancement by IL-5 in human
eosinophils. IL-5 and the stimulating agents were added
simultaneously
Leukotriene concentration (ng/106 cells)
IL-5
(U/ml) Donor Donor 2 Donor 3
0 1.38 6.32 3.55
10 3.09 16.83 2.00
100 2.69 12.26 2.24
000 5.37 20.55 8.70
(Table 3). The reason for this variability is unclear
at present, but others have reported similar donor
variation.
15
Discussion
In the present study, it is demonstrated that IL-5
potentiates leukotriene production of human
eosinophils stimulated with serum treated zymosan
or calcium ionophore. It has been shown that
GM-CSF enhances A23187-induced leukotriene
synthesis by eosinophils by approximately 135%.
15
However, in contrast to the priming of eosinophil
leukotriene production by GM-CSF,
15 the priming
by IL-5 does not increase with time. Similar
immediate priming effects have been demonstrated
in the basophil with IL-5 induced potentiation of
histamine release and leukotriene generation.2’21
The potentiation of A23187 induced leukotriene
synthesis by IL-5 is more evident and occurs at
lower concentrations than STZ induced leukotriene
synthesis. The reason for this difference is unclear
but could be due to differences in the signal
transduction pathways between STZ and A23187
stimulation.
It has been demonstrated that eosinophils from
asthmatic patients have an increased capacity to
produce leukotriene after stimulation.
2 Other
eosinophil functions in asthmatics such as the
production of reactive oxygen metabolites appear
to be primed as well. 2’12 T-lymphocyte derived
cytokines are potential candidates for the induction
of a primed state in eosinophils in asthma as these
cells are activated in acute asthma.
12 IL-5 mRNA
expression has been demonstrated in the bronchial
rnucosa and bronchoalveolar lavage cells of
asthmatics.22’23 Eosinophil derived mediators seem
to play an important role in the development of
airway hyperreactivity.
1-3 Interestingly, we demon-
strated that antibody to IL-5 prevented the
antigen-induced airway hyperreactivity and eosino-
phil infiltration in ovalbumin sensitized guinea-
pigs.
24 Vice versa, administration of IL-5 to
guinea-pigs induced airway eosinophilia and
hyperreactivity.24’25 Based on these data, together
with the present findings, it can be speculated that
IL-5 may play an important role in the pathogenesis
of asthma.
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